Literature DB >> 27121245

Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer.

Pinar Polat1, Peter D Donofrio2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27121245     DOI： 10.1002/mus.25163

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  11 in total

1.  Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

Authors:  Justin C Kao; Bing Liao; Svetomir N Markovic; Christopher J Klein; Elie Naddaf; Nathan P Staff; Teerin Liewluck; Julie E Hammack; Paola Sandroni; Heidi Finnes; Michelle L Mauermann
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

2.  Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

Authors:  James Larkin; Bartosz Chmielowski; Christopher D Lao; F Stephen Hodi; William Sharfman; Jeffrey Weber; Karijn P M Suijkerbuijk; Sergio Azevedo; Hewei Li; Daniel Reshef; Alexandre Avila; David A Reardon
Journal:  Oncologist       Date:  2017-05-11

Review 3.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250

Review 4.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

5.  Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.

Authors:  Yu-Hsiu Chen; Feng-Cheng Liu; Chang-Hung Hsu; Chih-Feng Chian
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

6.  Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.

Authors:  Asako Onda; Shinji Miyagawa; Naoko Takahashi; Mina Gochi; Masamichi Takagi; Ichizo Nishino; Shigeaki Suzuki; Chizuko Oishi; Hiroshi Yaguchi
Journal:  Intern Med       Date:  2019-02-01       Impact factor: 1.271

Review 7.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

Review 8.  Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.

Authors:  Jia-Hung Chen; Kang-Yun Lee; Chaur-Jong Hu; Chen-Chih Chung
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  Brachial Plexus Neuritis Associated With Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases.

Authors:  Reem M Alhammad; Roxanna S Dronca; Lisa A Kottschade; Heidi J Turner; Nathan P Staff; Michelle L Mauermann; Jennifer A Tracy; Christopher J Klein
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2017-09-01

Review 10.  Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.

Authors:  Lin Zhou; Xin Wei
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.